Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C13H19AsN2O5S |
| Molecular Weight | 390.287 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)(SCC(=O)NC1=CC=C(C=C1)[As](O)O)[C@@H](N)C(O)=O
InChI
InChIKey=BTIKNFALDXFWCX-NSHDSACASA-N
InChI=1S/C13H19AsN2O5S/c1-13(2,11(15)12(18)19)22-7-10(17)16-9-5-3-8(4-6-9)14(20)21/h3-6,11,20-21H,7,15H2,1-2H3,(H,16,17)(H,18,19)/t11-/m0/s1
| Molecular Formula | C13H19AsN2O5S |
| Molecular Weight | 390.287 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:43:10 GMT 2023
by
admin
on
Sat Dec 16 11:43:10 GMT 2023
|
| Record UNII |
HH7VUN8QBQ
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
16049815
Created by
admin on Sat Dec 16 11:43:10 GMT 2023 , Edited by admin on Sat Dec 16 11:43:10 GMT 2023
|
PRIMARY | |||
|
1192411-43-0
Created by
admin on Sat Dec 16 11:43:10 GMT 2023 , Edited by admin on Sat Dec 16 11:43:10 GMT 2023
|
PRIMARY | |||
|
HH7VUN8QBQ
Created by
admin on Sat Dec 16 11:43:10 GMT 2023 , Edited by admin on Sat Dec 16 11:43:10 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
A Phase I study of 4-(N-(S-penicillaminylacetyl)amino) phenylarsonous acid (PENAO) given as a continuous intravenous infusion, to patients with advanced solid tumours (Other ID's: U1111-1133-4715)
|
||
|
ACTIVE MOIETY |
RESULTS: PENAO demonstrated promising anti-proliferative activity on the most common (serous, endometrioid) as well as on rare (clear cell, mucinous) subtypes of ovarian cancer cell lines. No cross-resistance with platinum-based drugs was evident. Endometrioid SKOV-3 cells were, however, shown to be resistant to PENAO in vitro and in a xenograft mouse model. This resistance was due to an ability to cope with PENAO-induced oxidative stress, notably through heme oxygenase-1 induction, and a shift in metabolism towards glycolysis. The adaptive glycolytic shift in SKOV-3 was targeted using a mTORC1 inhibitor in combination with PENAO. This strategy was successful with the two drugs acting synergistically to inhibit cell proliferation and to induce cell death via apoptosis and autophagy.
|
